Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 13, Issue 3, Pages 241-250Publisher
SPRINGER
DOI: 10.1007/s11926-011-0174-x
Keywords
Osteoporosis; Bone quality; Radiography; Computed tomography; Magnetic resonance imaging; Image analysis
Categories
Funding
- Merck Co.
- Novartis
- Servier
- Bristol-Myers Squibb
- GlaxoSmithKline
- Roche
- Eli Lilly and Company
- Genentech
- Amgen
- Ono Pharmaceutical Co.
Ask authors/readers for more resources
The digital era has witnessed an exponential growth in bone imaging as new modalities and analytic techniques improve the potential for noninvasive study of bone anatomy, physiology, and pathophysiology. Bone imaging very much lends itself to input across medical and engineering disciplines. It is in part a reflection of this multidisciplinary input that developments in the field of bone imaging over the past 30 years have in some respects outshone those in many other fields of medicine. These developments have resulted in much deeper knowledge of bone macrostructure and microstructure in osteoporosis and a much better understanding of the subtle changes that occur with age, concurrent disease, and treatment. This new knowledge is already being translated into improved day-to day clinical care with better recognition, treatment, and monitoring of the osteoporotic process. As the more you know, the more you know you don't know certainly holds true with osteoporosis and bone disease, there is little doubt that further advances in bone imaging and analytical techniques will continue to hold center stage in osteoporosis and related research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available